[ad_1]
Aimovig is a development of Novartis and Amgen. The launch in the US has been unprecedented, said Novartis boss Vas Narasimhan, who calls it a good omen for the launch in Europe. Demand in the United States surprised us positively. Analysts predict that Novartis will reach a global turnover of $ 300 million for Aimovig.
Erenumab is a monoclonal antibody that can reduce the number of attacks and the use of badgesics in patients with chronic migraine. The drug specifically targets the calcitonin gene-related peptide receptor (CGRP), which is involved in the development and maintenance of migraine. CGRP is a messenger substance, which is increasingly released in a migraine attack and plays a central role as an inflammatory protein in migraine. The pro-inflammatory neuropeptide is responsible for vasodilatation.
The drug is not suitable for the acute treatment of a migraine attack. Antibody therapy is indicated for the prophylaxis of migraine in adults who have an attack for at least 4 days a month. Antibody therapy is injected once a month. Common adverse drug reactions include pain or injection site reactions, constipation, nausea, and upper respiratory tract infections. Aimovig is marketed as a 70 mg solution for injection
[ad_2]
Source link
